Cargando…
A Peptide in a Pill – Oral Semaglutide in the Management of Type 2 Diabetes
T2DM (type 2 diabetes mellitus) is a chronic and progressive illness with high morbidity and death rates. Oral semaglutide (Rybelsus®) is a combination of semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), and sodium N- (8- [2-hydroxybenzoyl] amino) caprylate (SNAC), an absorption e...
Autores principales: | Selvarajan, Raja, Subramanian, Rashmi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10259523/ https://www.ncbi.nlm.nih.gov/pubmed/37312901 http://dx.doi.org/10.2147/DMSO.S385196 |
Ejemplares similares
-
A Review of Oral Semaglutide Available Evidence: A New Era of Management of Diabetes with Peptide in a Pill Form
por: Kalra, Sanjay, et al.
Publicado: (2022) -
Oral Semaglutide In The Management Of Type 2 Diabetes: A Report On The Evidence To Date
por: Pearson, Sam, et al.
Publicado: (2019) -
Management of type 2 diabetes with oral semaglutide: Practical guidance for pharmacists
por: Kane, Michael P, et al.
Publicado: (2020) -
A Review on Semaglutide: An Oral Glucagon-Like Peptide 1 Receptor Agonist in Management of Type 2 Diabetes Mellitus
por: Kalra, Sanjay, et al.
Publicado: (2020) -
A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes
por: Aroda, Vanita R., et al.
Publicado: (2022)